We dedicated to providing inflammation total solution which consists of IL-6, PCT and sCD14-ST to meet different clinical demands from our end-users.
sCD14-ST (the soluble subtype of CD14 ) or presepsin, is a glycoprotein fragment derived from monocytes and macrophage. It is an innate direct response biomarker of activation of immune cell responding towards an invading pathogen. Compared to PCT induced by cytokines after bacterial phagocytosis, sCD14-ST is a more direct infectious biomarker, which ismediated by pathogens.
We dedicated to providing inflammation total solution which consists of IL-6, PCT and sCD14-ST to meet different clinical demands from our end-users.
sCD14-ST (the soluble subtype of CD14 ) or presepsin, is a glycoprotein fragment derived from monocytes and macrophage. It is an innate direct response biomarker of activation of immune cell responding towards an invading pathogen. Compared to PCT induced by cytokines after bacterial phagocytosis, sCD14-ST is a more direct infectious biomarker, which ismediated by pathogens.
Studies on pathological mechanism and clinical trials have revealed that sCD14-ST is important for the clinical managementof infectious diseases or related conditions, such as neonatal sepsis, prosthetic joint infection(PJI), febrile neutropenia(FN),sepsis and early infection in trauma.
sCD14-ST is a valuable biomarker for neonate sepsis, playing an important role in the rapid assessment and evaluation of severity. sCD14-ST levels in neonates with sepsis are signi cantly higher than those of the non-infective SIRS and normal control groups, suggesting that it could be an indicator for the identi cation of infective and non-infective SIRS.
sCD14-ST levels at T0 were significantly higher in neonates with sepsis and sepsis shock compared to those with infection. During the first 48h from the onset of symptoms, sCD14-ST progressively increased in neonates with septic shock, while it remained stable or decreased in neonates with sepsis or infection.
sCD14-ST is a potential inflammation biomarker for the diagnosis and prognosis of PJI. Research has shown that sCD14-ST levelswere significantly higher in PJI patients than controls. Post-operative levels of sCD14-ST in PJI patients dropped significantly with longer recovery time, while sCD14-ST levels remained unchanged and significantly lower in non-infected patients.
sCD14-ST is an early diagnostic marker of febrile neutropenia in hematologic malignancy patients. In a related case study,elevated levels of sCD14-ST was observed one day prior to CRP. Plasma sCD14-ST level is a reliable marker of FN even incases of extremely low WBC counts. Further, evaluation of increase rate can facilitate early diagnosis of FN in patients with myeloid and lymphoid disorders. Closer monitoring of this molecule could prevent infection-associated death inhematologic malignancy cases.
sCD14-ST is a superior biomarker for early differentiation of infection in trauma patients. Plasma sCD14-ST levels within the first 3 days of admission were only significantly increased in the infected trauma group, but not in the non-infected trauma and sterile group. sCD14-ST is also specified in the presence of infection in trauma patients.
Our mission is to support healthcare professionals with tools that enhance safety, comfort, and performance.
© 2025 Trade Visions International. All Rights Reserved.
Design and Developed By Wolfiz
